Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes

References

• Michels AW, Landry LG, McDaniel KA, et al. Islet-Derived CD4 T cells targeting proinsulin in human autoimmune diabetes. Diabetes. 2017;66(3):722–734.
   PubMed Web of Science ®Google Scholar
• Noble JA. Immunogenetics of type 1 diabetes: a comprehensive review. J Autoimmun. 2015;64:101–112.
   PubMed Web of Science ®Google Scholar
• Steck AK, Vehik K, Bonifacio E, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Dia Care. 2015;38(5):808–813.
   PubMed Web of Science ®Google Scholar
• Lampasona V, Liberati D. Islet autoantibodies. Curr Diab Rep. 2016;16(6):53.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191(3):411–416.
   PubMed Web of Science ®Google Scholar
• Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol. 2013;5(1):a008748–a008748.
   PubMed Web of Science ®Google Scholar
• Marin-Gallen S, Clemente-Casares X, Planas R, et al. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol. 2009;160(2):207–214.
   PubMed Web of Science ®Google Scholar
• Pujol-Autonell I, Serracant-Prat A, Cano-Sarabia M, et al. Use of Autoantigen-Loaded Phosphatidylserine-Liposomes to arrest autoimmunity in Type 1 diabetes. Plos One. 2015; 10(6): e0127057.
   Web of Science ®Google Scholar
• Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980;29(1):1–13.
   PubMedGoogle Scholar
• Chen Y-G, Mathews CE, Driver JP. The role of NOD mice in type 1 diabetes research: lessons from the past and recommendations for the future. Front Endocrinol. 2018;9:51.
   PubMed Web of Science ®Google Scholar
• Harel-Adar T, Mordechai T, Ben Amsalem Y, et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci USA. 2011;108(5):1827–1832.
   PubMed Web of Science ®Google Scholar
• Alba A, Puertas MC, Carrillo J, et al. IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol. 2004;173(11):6667–6675.
   PubMed Web of Science ®Google Scholar
• Zúñiga JM, Orellana Muriana JM, Tur Marí JA, Ciencia y tecnología del animal de laboratorio. Universidad de Alcalá. 2013;1:151–182.
   Google Scholar
• Pujol-Autonell I, Mansilla M-J, Rodriguez-Fernandez S, et al. Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis. Nanomedicine. 2017;12(11):1231–1242.
   PubMed Web of Science ®Google Scholar
• Nakayama M. Insulin as a key autoantigen in the development of type 1 diabetes. Diabetes Metab Res Rev. 2011;27(8):773–777.
   PubMed Web of Science ®Google Scholar
• Giannopoulou EZ, Winkler C, Chmiel R, et al. Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes. Diabetologia. 2015;58(10):2317–2323.
   PubMed Web of Science ®Google Scholar
• Solimena M, Dirkx R, Hermel JM, et al. ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. Embo J. 1996;15(9):2102–2114.
   PubMed Web of Science ®Google Scholar
• Takeyama N, Ano Y, Wu G, et al. Localization of insulinoma associated protein 2, IA-2 in mouse neuroendocrine tissues using two novel monoclonal antibodies. Life Sci. 2009;84(19–20):678–687.
   PubMed Web of Science ®Google Scholar
• Mally MI, Cirulli V, Otonkoski T, et al. Ontogeny and tissue distribution of human GAD expression. Diabetes. 1996;45(4):496–501.
   PubMed Web of Science ®Google Scholar
• Funda DP, Goliáš J, Hudcovic T, et al. Antigen loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) reduces their capacity to prevent diabetes in the Non-Obese Diabetes (NOD)-severe combined immunodeficiency model of adoptive cotransfer of diabetes as well as in NOD mice. Front Immunol. 2018;9:290.
   PubMed Web of Science ®Google Scholar
• Mallone R, Brezar V, Boitard C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol. 2011;2011:1.
   Google Scholar
• Rudy G, Stone N, Harrison LC, et al. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol Med. 1995;1(6):625–633.
   PubMed Web of Science ®Google Scholar
• So M, Elso CM, Tresoldi E, et al. Proinsulin C-peptide is an autoantigen in people with type 1 diabetes. Proc Natl Acad Sci USA. 2018;115(42):10732–10737.
   PubMed Web of Science ®Google Scholar
• Peakman M, Dayan CM. Antigen-specificc immunotherapy for autoimmune disease: fighting fire with fire? Immunology. 2001;9:290.
   Google Scholar
• Fierabracci A. Peptide immunotherapies in Type 1 diabetes: lessons from animal models. Curr Med Chem. 2011;18(4):577–586.
   PubMed Web of Science ®Google Scholar
• Shen L, Lu S, Huang D, et al. A rationally designed peptide IA-2-P2 against type 1 diabetes in streptozotocin-induced diabetic mice. Diabetes Vasc Dis Res. 2017;14(3):184–190.
   PubMed Web of Science ®Google Scholar